In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Arvinas Holding Company, with a price target of $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Derek Archila has given his Buy rating due to a combination of factors including Arvinas Holding Company’s strong cash position and promising early-stage pipeline. Despite uncertainties surrounding the commercial future of vepdeg, the company has a cash runway extending into the second half of 2028, which provides a solid financial foundation to support ongoing research and development efforts.
Moreover, Arvinas is advancing several promising programs such as ARV-102 and ARV-393, with upcoming data readouts that could potentially drive value. The company’s strategic focus on its early-stage assets, coupled with the potential for alternative partnerships if vepdeg is returned by Pfizer, underpins the positive outlook. Archila believes that the current stock price, which is trading below cash value, may not fully reflect the potential of these pipeline opportunities, thus justifying the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $16.00 price target.
ARVN’s price has also changed dramatically for the past six months – from $19.100 to $6.430, which is a -66.34% drop .